Similar articles

• Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.

  Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Stevens TP, et al. Arch Pediatr Adolesc Med. 2000 Jan;154(1):55-61. Arch Pediatr Adolesc Med. 2000. PMID: 10632251
• RSV disease--is there a role for prevention?

  Lenney W. Lenney W. Respir Med. 2001 Mar;95(3):170-2. doi: 10.1053/rmed.2000.1018. Respir Med. 2001. PMID: 11266232 No abstract available.
• Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.

  Mahadevia PJ, Malinoski FJ. Mahadevia PJ, et al. Arch Pediatr Adolesc Med. 2007 May;161(5):519-20; author reply 520. doi: 10.1001/archpedi.161.5.519. Arch Pediatr Adolesc Med. 2007. PMID: 17485634 No abstract available.
• Health economics and RSV.

  Carbonell-Estrany X, Lázaro y de Mercado P. Carbonell-Estrany X, et al. Paediatr Respir Rev. 2009 Jun;10 Suppl 1:12-3. doi: 10.1016/S1526-0542(09)70006-5. Paediatr Respir Rev. 2009. PMID: 19651392 Review.
• Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?

  Geskey JM, Ceneviva GD, Brummel GL, Graff GR, Javier MC. Geskey JM, et al. Clin Ther. 2004 Dec;26(12):2130-7. doi: 10.1016/j.clinthera.2004.12.005. Clin Ther. 2004. PMID: 15823776 Review.